Survival of Chinese Patients With Pulmonary Arterial Hypertension in the Modern Treatment Era

医学 内科学 肺动脉 心脏病学 肺动脉高压 存活率 心包积液 肺楔压
作者
Rui Zhang,Li-Zhi Dai,Weiping Xie,Zaixin Yu,WU Bing-xiang,Lei Pan,Ping Yuan,Xin Jiang,Jing He,Marc Humbert,Zhi‐Cheng Jing
出处
期刊:Chest [Elsevier]
卷期号:140 (2): 301-309 被引量:180
标识
DOI:10.1378/chest.10-2327
摘要

In a previous study of Chinese patients with idiopathic pulmonary arterial hypertension (IPAH) in the nontargeted therapy era (defined as the time before 2006 when new pulmonary arterial hypertension-specific drugs were not available in China), we reported 1- and 3-year survival estimates of only 68% and 39%, respectively. However, it is not yet known whether the survival of patients with pulmonary arterial hypertension is improved in the modern treatment era (defined in China as after 2006).A retrospective cohort study was undertaken in 276 consecutive patients with newly diagnosed incident IPAH and connective tissue disease-related pulmonary arterial hypertension (CTDPAH) who were referred between 2007 and 2009. Baseline characteristics and survival rates in the two groups were compared.The 1- and 3-year survival estimates were 92.1% and 75.1%, respectively, in patients with IPAH, and 85.4% and 53.6%, respectively, in patients with CTDPAH. Patients with CTDPAH had a significantly lower mean pulmonary artery pressure, more pericardial effusion, and more severe impairment of the diffusion capacity of the lung for carbon monoxide than patients with IPAH. A diagnosis of CTDPAH, World Health Organization functional class III or IV, single-breath diffusion capacity of the lung for carbon monoxide < 80% predicted, and the presence of pericardial effusion were independent predictors of mortality. The 1- and 3-year survival rates of male patients were 93.5% and 77.5%, respectively, in those with IPAH, and 71.1% and 47.4%, respectively, in those with CTDPAH.The survival rates of patients with pulmonary arterial hypertension have improved in China in the modern treatment era, despite the high costs of treatment and financial constraints. However, the survival rates of patients with CTDPAH are inferior to those of patients with IPAH. Our study also indicates poorer survival rates in male patients with CTDPAH.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
凹凸蔓发布了新的文献求助10
1秒前
WLWLW应助AAAA采纳,获得10
2秒前
yangjoy完成签到 ,获得积分10
2秒前
爆米花应助合适孤兰采纳,获得10
5秒前
6秒前
debu9驳回了赘婿应助
7秒前
科研通AI2S应助高贵的画笔采纳,获得10
7秒前
清辉夜凝发布了新的文献求助10
8秒前
天天快乐应助Anthocyanidin采纳,获得10
8秒前
RW发布了新的文献求助10
9秒前
pluto应助Linda采纳,获得60
9秒前
Kitty完成签到,获得积分10
10秒前
11秒前
12秒前
12秒前
angel完成签到,获得积分10
12秒前
打打应助cxw采纳,获得10
13秒前
科研通AI2S应助旋风小土豆采纳,获得10
15秒前
xiao发布了新的文献求助10
15秒前
smile发布了新的文献求助30
16秒前
16秒前
二二完成签到,获得积分10
17秒前
CodeCraft应助维尼采纳,获得10
18秒前
FashionBoy应助菜菜的阿荣采纳,获得10
20秒前
Linda完成签到,获得积分10
20秒前
21秒前
Jiawww发布了新的文献求助10
21秒前
英姑应助CC采纳,获得10
23秒前
Lucas应助凹凸蔓采纳,获得10
23秒前
24秒前
平常梦岚完成签到,获得积分10
24秒前
zgy1106完成签到,获得积分10
24秒前
积极的沛蓝完成签到,获得积分10
25秒前
李健的小迷弟应助dxy采纳,获得10
25秒前
Ting222发布了新的文献求助10
26秒前
c123完成签到,获得积分10
28秒前
29秒前
30秒前
30秒前
田様应助windcreator采纳,获得10
31秒前
高分求助中
The late Devonian Standard Conodont Zonation 2000
Nickel superalloy market size, share, growth, trends, and forecast 2023-2030 2000
The Lali Section: An Excellent Reference Section for Upper - Devonian in South China 1500
Very-high-order BVD Schemes Using β-variable THINC Method 890
Mantiden: Faszinierende Lauerjäger Faszinierende Lauerjäger 800
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 800
Saponins and sapogenins. IX. Saponins and sapogenins of Luffa aegyptica mill seeds (black variety) 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3259719
求助须知:如何正确求助?哪些是违规求助? 2901251
关于积分的说明 8314762
捐赠科研通 2570769
什么是DOI,文献DOI怎么找? 1396658
科研通“疑难数据库(出版商)”最低求助积分说明 653554
邀请新用户注册赠送积分活动 631833